JP2017527544A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017527544A5 JP2017527544A5 JP2017506827A JP2017506827A JP2017527544A5 JP 2017527544 A5 JP2017527544 A5 JP 2017527544A5 JP 2017506827 A JP2017506827 A JP 2017506827A JP 2017506827 A JP2017506827 A JP 2017506827A JP 2017527544 A5 JP2017527544 A5 JP 2017527544A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 239000012634 fragment Substances 0.000 claims 19
- 229940106189 ceramide Drugs 0.000 claims 15
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000005855 radiation Effects 0.000 claims 4
- 230000006907 apoptotic process Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 238000007913 intrathecal administration Methods 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462034453P | 2014-08-07 | 2014-08-07 | |
| US62/034,453 | 2014-08-07 | ||
| PCT/US2015/044144 WO2016022883A1 (en) | 2014-08-07 | 2015-08-07 | Anti-ceramide antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017527544A JP2017527544A (ja) | 2017-09-21 |
| JP2017527544A5 true JP2017527544A5 (cg-RX-API-DMAC7.html) | 2018-09-13 |
| JP6670297B2 JP6670297B2 (ja) | 2020-03-18 |
Family
ID=55264608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017506827A Active JP6670297B2 (ja) | 2014-08-07 | 2015-08-07 | 抗セラミド抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US10450385B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3177650B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6670297B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102296416B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107074949B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015300902B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2957415C (cg-RX-API-DMAC7.html) |
| IL (1) | IL250374B (cg-RX-API-DMAC7.html) |
| MX (1) | MX391141B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2717651C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201700787XA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016022883A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017228474C1 (en) | 2016-03-04 | 2024-03-28 | Abmuno Therapeutics Llc | Antibodies to TIGIT |
| JP7264482B2 (ja) * | 2016-12-23 | 2023-04-25 | ブルーフィン バイオメディシン, インコーポレイテッド | 抗sez6l2抗体および抗体薬物コンジュゲート |
| US20200362057A1 (en) | 2019-05-16 | 2020-11-19 | Snake River Bioscience, Inc. | Compositions and methods for the treatment of major depressive disorder |
| CN113906051B (zh) * | 2019-06-06 | 2025-06-06 | 北京加科思新药研发有限公司 | 对cd73具有特异性的结合分子及其用途 |
| US10975169B1 (en) * | 2019-09-27 | 2021-04-13 | Memorial Sloan Kettering Cancer Center | Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2 |
| KR102245082B1 (ko) * | 2020-02-14 | 2021-04-26 | 단국대학교 천안캠퍼스 산학협력단 | 치주인대전구세포 표면에 특이적으로 결합하는 두 가지 IgG 타입 단일클론항체 LG43, LG73 및 그의 용도 |
| WO2021188770A1 (en) * | 2020-03-18 | 2021-09-23 | Memorial Sloan Kettering Cancer Center | Anti-ceramide antibodies |
| EP4157875A1 (en) | 2020-06-02 | 2023-04-05 | Arcus Biosciences, Inc. | Antibodies to tigit |
| KR20230162788A (ko) * | 2021-03-16 | 2023-11-28 | 메모리얼 슬로안 케터링 캔서 센터 | 항-세라마이드 항체를 이용한 상처 치유 증진 |
| WO2024226646A2 (en) * | 2023-04-25 | 2024-10-31 | Memorial Sloan-Kettering Cancer Center | Dlk1 -targeting antibodies and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| JPH02128697A (ja) | 1988-11-09 | 1990-05-17 | Hoechst Japan Ltd | 抗フコシルセラミドモノクローナル抗体 |
| US7897753B2 (en) * | 2002-02-20 | 2011-03-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA) |
| RU2310393C1 (ru) | 2006-02-16 | 2007-11-20 | ФГУ Научно-исследовательский институт по изучению лепры Федерального агентства по здравоохранению и социальному развитию Российской Федерации | Способ прогнозирования обострений лепрозных невропатий у больных лепрой |
| JP5924863B2 (ja) | 2007-05-06 | 2016-05-25 | スローン ケタリング インスティテュート フォア キャンサー リサーチ | Gi症候群及び移植片対宿主病を治療及び予防する方法 |
| US9163091B2 (en) | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
| US8410251B2 (en) * | 2008-06-20 | 2013-04-02 | National University Corporation Okayama University | Antibody against calcified globule and use of the same |
| KR101050829B1 (ko) * | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 항암제 |
| US9090679B2 (en) * | 2009-04-17 | 2015-07-28 | Immunas Pharma, Inc. | Antibodies that specifically bind to A beta oligomers and use thereof |
| FR2971250A1 (fr) * | 2011-02-07 | 2012-08-10 | Univ Nantes | Anticorps anti-gb3 utiles dans le traitement des maladies associees a l'angiogenese |
| KR101256351B1 (ko) | 2011-11-22 | 2013-04-19 | 김석진 | 필터 삽입공을 갖는 카메라 후드 |
| RU2631804C2 (ru) * | 2012-02-21 | 2017-09-26 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения или профилактики рака |
| EP2854850B1 (en) * | 2012-05-25 | 2021-05-26 | Sloan Kettering Institute For Cancer Research | Compositions for treating or preventing radiation disease and gi syndrome |
| WO2021188770A1 (en) * | 2020-03-18 | 2021-09-23 | Memorial Sloan Kettering Cancer Center | Anti-ceramide antibodies |
-
2015
- 2015-08-07 MX MX2017001686A patent/MX391141B/es unknown
- 2015-08-07 EP EP15830378.4A patent/EP3177650B1/en active Active
- 2015-08-07 US US15/502,162 patent/US10450385B2/en active Active
- 2015-08-07 KR KR1020177006255A patent/KR102296416B1/ko active Active
- 2015-08-07 RU RU2017105596A patent/RU2717651C2/ru active
- 2015-08-07 SG SG11201700787XA patent/SG11201700787XA/en unknown
- 2015-08-07 AU AU2015300902A patent/AU2015300902B2/en active Active
- 2015-08-07 JP JP2017506827A patent/JP6670297B2/ja active Active
- 2015-08-07 CN CN201580048151.7A patent/CN107074949B/zh active Active
- 2015-08-07 CA CA2957415A patent/CA2957415C/en active Active
- 2015-08-07 WO PCT/US2015/044144 patent/WO2016022883A1/en not_active Ceased
-
2017
- 2017-01-31 IL IL250374A patent/IL250374B/en active IP Right Grant
-
2019
- 2019-09-11 US US16/568,152 patent/US11447572B2/en active Active
-
2022
- 2022-08-15 US US17/887,952 patent/US20230416409A1/en not_active Abandoned
-
2024
- 2024-07-31 US US18/790,647 patent/US20250197524A1/en active Pending